Stuart M. Cable

Stuart M. Cable

Partner Chair – M+A and Corporate Finance for Tech | Life Sciences
Stuart M. Cable

Stuart Cable represents as outside general counsel public and private companies involved in the life sciences and technology sectors. Mr. Cable also represents private equity and venture sources investing in such companies and investment banks serving such industries. He currently serves as the chair of the M&A and Corporate Finance practices for the firm’s Technology and Life Sciences business units. He previously served as chair of the firm’s Corporate Department, as chair of its Hiring Committee, as chair of its Incubator, and as a member of the firm's Executive and Allocations Committees.

Areas of Practice
Domaines de Pratique





Mr. Cable represents as outside general counsel a number of private and public companies, where he counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters.

Representative M&A transactions in the past five years include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the majority sale of Foundation Medicine to Roche ($1 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the private company sale of Stemcentrix to Abbvie ($5.8 billion), the sale of Opower to Oracle ($600 million), the acquisition of NXP by Qualcomm ($47 billion), the acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain) by AMRI, the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion), the private company acquisition of Cord Blood Registry by AMAG Pharmaceuticals ($700 million), the 2017 sale of Neustar to Golden Gate ($2.9 billion), the 2017 sale of Lionbridge to HIG ($400 million), the 2017 sale of AMRI to Carlyle and GTCR ($1.9 billion), the 2017 sale of PAREXEL to Pamplona ($5 billion), the 2017 cross border sale of inviCRO to Konica Minolta (Japan), and the $4 billion partnership between KIND and Mars. In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions.

Mr. Cable also represents public companies in connection with highly confidential “activist” matters, including the successful negotiation of "Cooperation" Agreements with Elliott Management on behalf of Cognizant and Citrix.

Mr. Cable serves regularly as counsel in IPOs (recently representing J.P. Morgan in the cross-border IPO of Trivago), follow-on offerings, and convertible debt transactions including the $1.5 billion convertible debt issuance by Citrix and representing Cornerstone onDemand in the 2017 $300 million strategic PIPE by Silver Lake and Microsoft.

Mr. Cable regularly represents investment banks, including J.P. Morgan, Morgan Stanley, Citibank and Centerview Partners in M&A and Corporate Finance transactions.

Mr. Cable also represents a number of private venture backed life sciences companies in governance, capital formation and collaboration transactions (including Moderna, Rubius and Yumanity).


Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College and as chairman emeritus of the Buckingham Browne & Nichols School. He has also served for more than a decade as a member of the Board of Fellows of Harvard Medical School. Mr. Cable leads the firm’s Pro Bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth.


Mr. Cable is annually ranked in Chambers USA: America’s Leading Lawyers for Business (Corporate/M&A – Band 1), Chambers Global: The Leading Lawyers for Business (Corporate/M&A) and U.S. News-Best Lawyers (Corporate Law). Global M&A Network has named him one of the world’s top 50 M&A lawyers, recognizing his work advising Onyx Pharmaceuticals in its $10.4 billion purchase by Amgen – a transaction named 2014 Global Major Markets Life Sciences Deal of the Year. Mr. Cable also was recognized by the Financial Times in both 2015 and 2016, winning its award for Innovative Deal of the Year in advising Foundation Medicine in its $1 billion majority purchase by Roche, and in 2016 advising Citrix in its $2.6 billion Reverse Morris Trust merger with LogMeIn. In 2016, Mr. Cable was recognized by LMG as Life Sciences Transaction Attorney of the Year. In 2017, Mr. Cable was recognized by Law360 as its Life Sciences MVP.

In The News


Dans les Nouvelles




Lettres de Créance



J.D., 1979
Columbia Law School

(Harlan Fiske Stone Scholar)

M.B.A., 1976
Tuck School of Business at Dartmouth
A.B., 1975
Dartmouth College

(magna cum laude)

Get In Touch
Entrer en contact
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos clients comptent sur nous pour des services de conseil de classe mondiale, des conseils sur le travail transactionnel complexe et des litiges à enjeux élevés. Spécialisés dans les domaines de la finance, des sciences de la vie, du capital-investissement, de l'immobilier et de la technologie, nous utilisons une approche collaborative et interdisciplinaire pour résoudre les problèmes les plus complexes de nos clients. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique